A.T. Scott, J.R. Howe, Evaluation and management of neuroendocrine tumors of the pancreas. Surg. Clin. North Am. 99, 793–814 (2019). https://doi.org/10.1016/j.suc.2019.04.014

Article  PubMed  PubMed Central  Google Scholar 

M. Falconi, B. Eriksson, G. Kaltsas, D.K. Bartsch, J. Capdevila, M. Caplin, B. Kos-Kudla, D. Kwekkeboom, G. Rindi, G. KlÖppel, N. Reed, R. Kianmanesh, R.T. Jensen, ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 153–171 (2016). https://doi.org/10.1159/000443171

A. Sowa-Staszczak, A. Hubalewska-Dydejczyk, M. Tomaszuk, PRRT as neoadjuvant treatment in NET. Recent Results Cancer Res. 479–485 (2013). https://doi.org/10.1007/978-3-642-27994-2_27

J.Y. Kim, S.M. Hong, J.Y. Ro, Recent updates on grading and classification of neuroendocrine tumors. Ann. Diagn. Pathol. 29, 11–16 (2017). https://doi.org/10.1016/j.anndiagpath.2017.04.005

Article  PubMed  Google Scholar 

G. Perri, L.R. Prakash, M.H.G. Katz, Pancreatic neuroendocrine tumors. Curr. Opin. Gastroenterol. 35, 468–477 (2019). https://doi.org/10.1097/MOG.0000000000000571

Article  CAS  PubMed  Google Scholar 

A. Rinke, T.M. Gress, Neuroendocrine cancer, therapeutic strategies in G3 cancers. Digestion 95, 109–114 (2017). https://doi.org/10.1159/000454761

Article  CAS  PubMed  Google Scholar 

D.L. Chan, R. Thompson, M. Lam, N. Pavlakis, J. Hallet, C. Law, S. Singh, S. Myrehaug, External beam radiotherapy in the treatment of gastroenteropancreatic neuroendocrine tumours: a systematic review. Clin. Oncol. 30, 400–408 (2018). https://doi.org/10.1016/j.clon.2018.03.006

Article  CAS  Google Scholar 

R.P. Baum, H.R. Kulkarni, A. Singh, D. Kaemmerer, D. Mueller, V. Prasad, M. Hommann, F.C. Robiller, K. Niepsch, H. Franz, A. Jochems, P. Lambin, D. Hörsch, Results and adverse events of personalized peptide receptor radionuclide therapy with 90 Yttrium and 177 Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget 9, 16932–16950 (2018)

G. Kong, R.J. Hicks, peptide receptor radiotherapy: current approaches and future directions. Curr. Treat. Options Oncol. 20 (2019). https://doi.org/10.1007/s11864-019-0677-7

J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz, M.H. Kulke, H. Jacene, D. Bushnell, T.M. O’Dorisio, R.P. Baum, H.R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J.L. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning, Phase 3 trial of 177 lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017). https://doi.org/10.1056/nejmoa1607427

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Ramage, B.G. Naraev, T.R. Halfdanarson, Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. Semin. Oncol. 45, 236–248 (2018). https://doi.org/10.1053/j.seminoncol.2018.08.004

Article  CAS  PubMed  Google Scholar 

T. Brabander, W.A. Van Der Zwan, J.J.M. Teunissen, B.L.R. Kam, R.A. Feelders, W.W. De Herder, C.H.J. Van Eijck, G.J.H. Franssen, E.P. Krenning, D.J. Kwekkeboom, Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin. Cancer Res. 23, 4617–4624 (2017). https://doi.org/10.1158/1078-0432.CCR-16-2743

L. Uccelli, A. Boschi, C. Cittanti, P. Martini, S. Panareo, E. Tonini, A. Nieri, L. Urso, M. Caracciolo, L. Lodi, A. Carnevale, M. Giganti, M. Bartolomei, 90Y/177Lu-DOTATOC: from preclinical studies to application in humans. Pharmaceutics 13 (2021). https://doi.org/10.3390/PHARMACEUTICS13091463

G. Paganelli, M. Sansovini, S. Nicolini, I. Grassi, T. Ibrahim, E. Amadori, V. Di Iorio, M. Monti, E. Scarpi, A. Bongiovanni, M. Altini, L. Urso, C. Cittanti, F. Matteucci, S. Severi, 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study, Eur. J. Nucl. Med. Mol. Imaging (2020). https://doi.org/10.1007/s00259-020-04873-0

D. Campana, G. Capurso, S. Partelli, F. Nori, F. Panzuto, D. Tamburrino, G. Cacciari, G. Delle Fave, M. Falconi, P. Tomassetti, Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: Factors associated with response and suggestions for therapeutic sequence. Eur. J. Nucl. Med. Mol. Imaging 40, 1197–1205 (2013). https://doi.org/10.1007/s00259-013-2402-2

Article  CAS  PubMed  Google Scholar 

S. Partelli, E. Bertani, M. Bartolomei, C. Perali, F. Muffatti, C.M. Grana, M. Schiavo Lena, C. Doglioni, S. Crippa, N. Fazio, G. Zamboni, M. Falconi, Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery 163, 761–767 (2018). https://doi.org/10.1016/j.surg.2017.11.007

Article  PubMed  Google Scholar 

M. Albertelli, A. Dotto, C. Di Dato, P. Malandrino, R. Modica, A. Versari, A. Colao, D. Ferone, A. Faggiano, PRRT: identikit of the perfect patient. Rev. Endocr. Metab. Disord. (2020). https://doi.org/10.1007/s11154-020-09581-6

C. Ricci, S. Pusceddu, N. Prinzi, S. Tafuto, T. Ibrahim, A. Filice, M.P. Brizzi, F. Panzuto, S. Baldari, C.M. Grana, D. Campana, M.V. Davì, D. Giuffrida, M.C. Zatelli, S. Partelli, P. Razzore, R. Marconcini, S. Massironi, F. Gelsomino, A. Faggiano, E. Giannetta, E. Bajetta, F. Grimaldi, M. Cives, F. Cirillo, V. Perfetti, F. Corti, C. Ricci, L. Giacomelli, L. Porcu, M. Di Maio, E. Seregni, M. Maccauro, S. Lastoria, A. Bongiovanni, A. Versari, I. Persano, M. Rinzivillo, S.A. Pignata, P.A. Rocca, G. Lamberti, S. Cingarlini, I. Puliafito, M.R. Ambrosio, I. Zanata, A. Bracigliano, S. Severi, F. Spada, V. Andreasi, R. Modica, F. Scalorbi, M. Milione, G. Sabella, J. Coppa, R. Casadei, M. Di Bartolomeo, M. Falconi, F. De Braud, Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors. JAMA Netw. Open 5, e220290–e220290 (2022). https://doi.org/10.1001/JAMANETWORKOPEN.2022.0290

Article  PubMed  PubMed Central  Google Scholar 

E. Giannetta, F. Sesti, R. Modica, E.M. Grossrubatscher, V. Guarnotta, A. Ragni, I. Zanata, A. Colao, A. Faggiano, Case report: unmasking hypercalcemia in patients with neuroendocrine neoplasms. Experience from six Italian referral centers. Front. Endocrinol. (Lausanne). 12, 1 (2021). https://doi.org/10.3389/FENDO.2021.665698

Article  Google Scholar 

G. Puliani, V. Di Vito, T. Feola, F. Sesti, R. Centello, C. Pandozzi, M.G. Tarsitano, M. Verrico, A. Lenzi, A.M. Isidori, E. Giannetta, A. Faggiano, NETest: a systematic review focusing on the prognostic and predictive role. Neuroendocrinology 112, 523–536 (2022). https://doi.org/10.1159/000518873

Article  CAS  PubMed  Google Scholar 

D. Kaemmerer, V. Prasad, W. Daffner, D. Hörsch, G. Klöppel, M. Hommann, R.P. Baum, Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J. Gastroenterol. 15, 5867–5870 (2009). https://doi.org/10.3748/wjg.15.5867

Article  PubMed  PubMed Central  Google Scholar 

S. Ezziddin, H. Lauschke, M. Schaefers, C. Meyer, M. Van Essen, H.J. Biersack, D.J. Kwekkeboom, H. Ahmadzadehfar, Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. Clin. Nucl. Med. 37, 102–104 (2012). https://doi.org/10.1097/RLU.0B013E318238F111

Article  PubMed  Google Scholar 

E.I. van Vliet, C.H. van Eijck, R.R. de Krijger, E.J.N. van Dijkum, J.J. Teunissen, B.L. Kam, W.Wde. Herder, R.A. Feelders, B.A. Bonsing, T. Brabander, E.P. Krenning, D.J. Kwekkeboom, Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3] octreotate. J. Nucl. Med. 56, 1647–1653 (2015). https://doi.org/10.2967/JNUMED.115.158899

T.N. da Silva, M.L.F. van Velthuysen, C.H.J. van Eijck, J.J. Teunissen, J. Hofland, W.W. de Herder, Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. Endocrinol. Diabetes Metab. Case Rep. 2018 (2018). https://doi.org/10.1530/edm-18-0015

I. Zanata, M.R. Ambrosio, M.C. Zatelli, Neoadjuvant PRRT for advanced pNEN: an unusual highlander. Endocrine 73, 493–495 (2021). https://doi.org/10.1007/s12020-021-02662-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

R.V. Parghane, M. Bhandare, V. Chaudhari, V. Ostwal, A. Ramaswamy, S. Talole, S.V. Shrikhande, S. Basu, Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177Lu-Dotatate PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 62, 1558–1563 (2021). https://doi.org/10.2967/jnumed.120.258772

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Opalińska, A. Sowa-Staszczak, A. Grochowska, H. Olearska, A. Hubalewska-Dydejczyk, Value of peptide receptor radionuclide therapy as neoadjuvant treatment in the management of primary inoperable neuroendocrine tumors. Front. Oncol. 11, 1–8 (2021). https://doi.org/10.3389/fonc.2021.687925

Article  Google Scholar 

T.W. Barber, M.S. Hofman, B.N.J. Thomson, R.J. Hicks, The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur. J. Surg. Oncol. 38, 64–71 (2012). https://doi.org/10.1016/j.ejso.2011.08.129

Article  CAS  PubMed  Google Scholar 

N.S. Minczeles, C.H.J. van Eijck, M.J. van Gils, M.L.F. van Velthuysen, E.J.M. Nieveen van Dijkum, R.A. Feelders, W.W. de Herder, T. Brabander, J. Hofland. Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. Eur. J. Nucl. Med. Mol. Imaging 1–12 (2022). https://doi.org/10.1007/S00259-022-05734-8/TABLES/5

J. Strosberg, P.L. Kunz, A. Hendifar, J. Yao, D. Bushnell, M.H. Kulke, R.P. Baum, M. Caplin, P. Ruszniewski, E. Delpassand, T. Hobday, C. Verslype, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, G. Paganelli, S. Severi, M. Morse, D.C. Metz, C. Ansquer, F. Courbon, A. Al-Nahhas, E. Baudin, F. Giammarile, D. Taïeb, E. Mittra, E. Wolin, T.M. O’Dorisio, R. Lebtahi, C.M. Deroose, C.M. Grana, L. Bodei, K. Öberg, B.D. Polack, B. He, M.F. Mariani, G. Gericke, P. Santoro, J.L. Erion, L. Ravasi, E. Krenning, Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur. J. Nucl. Med. Mol. Imaging 47, 2372–2382 (2020). https://doi.org/10.1007/s00259-020-04709-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Schiavo Lena, S. Partelli, P. Castelli, V. Andreasi, C.E. Smart, E. Pisa, M. Bartolomei, E. Bertani, G. Zamboni, M. Falconi, C. Doglioni, Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT). Endocr. Pathol. 31, 119–131 (2020). https://doi.org/10.1007/s12022-020-09623-4

F. Panzuto, S. Puscedddu, A. Faggiano, M. Rinzivillo, N. Brighi, N. Prinzi, F. Riccardi, E. Iannicelli, I. Maggio, D. Femia, S. Tafuto, L. Manuzzi, A. Di Sarno, B. Annibale, F. de Braud, D. Campana, Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: a comparison between pancreatic and gastrointestinal localizations. Pancreatology 19, 1067–1073 (2019). https://doi.org/10.1016/j.pan.2019.09.015

Article  PubMed  Google Scholar 

J.R. Howe, N.B. Merchant, C. Conrad, X.M. Keutgen, J. Hallet, J.A. Drebin, R.M. Minter, T.C. Lairmore, J.F. Tseng, H.J. Zeh, S.K. Libutti, G. Singh, J.E. Lee, T.A. Hope, M.K. Kim, Y. Menda, T.R. Halfdanarson, J.A. Chan, R.F. Pommier, The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49, 1–33 (2020). https://doi.org/10.1097/MPA.0000000000001454

Article  PubMed  PubMed Central  Google Scholar 

O. Stoeltzing, E. Huber, M. Loss, V. Gross, C. Eilles, J. Mueller-Brand, H.J. Schlitt, Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbeck’s Arch. Surg. 395, 185–192 (2010). https://doi.org/10.1007/s00423-009-0520-x

Article  Google Scholar 

M.H. Squires, P.J. Worth, B. Konda, M.H. Shah, M.E. Dillhoff, S. Abdel-Misih, J.A. Norton, B.C. Visser, M. Dua, T.M. Pawlik, C.R. Schmidt, G. Poultsides, J.M. Cloyd, Neoadjuvant capecitabine/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors. Pancreas 355–360 (2020). https://doi.org/10.1097/MPA.0000000000001500

S. Nicolini, L. Bodei, A. Bongiovanni, M. Sansovini, I. Grassi, T. Ibrahim, M. Monti, P. Caroli, A. Sarnelli, D. Diano, V. Di Iorio, C.M. Grana, C. Cittanti, F. Pieri, S. Severi, G. Paganelli, Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging (2021). https://doi.org/10.1007/s00259-021-05236-z/Published

J.R. Strosberg, M.E. Caplin, P.L. Kunz, P.B. Ruszniewski, L. Bodei, A. Hendifar, E. Mittra, E.M. Wolin, J.C. Yao, M.E. Pavel, E. Grande, E. Van Cutsem, E. Seregni, H. Duarte, G. Gericke, A. Bartalotta, M.F. Mariani, A. Demange, S. Mutevelic, E.P. Krenning, 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 1752–1763 (2021). https://doi.org/10.1016/S1470-2045(21)00572-6

Article  CAS  PubMed  Google Scholar 

K. Sjögreen Gleisner, N. Chouin, P.M. Gabina, F. Cicone, S. Gnesin, C. Stokke, M. Konijnenberg, M. Cremonesi, F.A. Verburg, P. Bernhardt, U. Eberlein, J. Gear, EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur. J. Nucl. Med. Mol. Imaging (2022). https://doi.org/10.1007/s00259-022-05727-7

U. Garske-Román, M. Sandström, K. Fröss Baron, L. Lundin, P. Hellman, S. Welin, S. Johansson, T. Khan, H. Lundqvist, B. Eriksson, A. Sundin, D. Granberg, Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur. J. Nucl. Med. Mol. Imaging 45, 970–988 (2018). https://doi.org/10.1007/s00259-018-3945-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

L. Bodei, M. Cremonesi, C.M. Grana, M. Chinol, S.M. Baio, S. Severi, G. Paganelli, Yttrium-labelled peptides for therapy of NET, Eur. J. Nucl. Med. Mol. Imaging 39, (2012). https://doi.org/10.1007/s00259-011-2002-y

L. Bodei, M. Cremonesi, G. Paganelli, Yttrium-based therapy for neuroendocrine tumors. PET Clin. 9, 71–82 (2014). https://doi.org/10.1016/j.cpet.2013.10.001

Article  PubMed  Google Scholar 

Neoadjuvant PRRT With 177Lu-DOTATATE followed by surgery for resectable PanNET. ClinicalTrials.gov (2022). https://clinicaltrials.gov/ct2/show/NCT04385992 (accessed 20 May 2022)